These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 26651387)

  • 1. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B; Philip DS; Shrikhande SV
    Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib for treatment of advanced gastrointestinal stromal tumors.
    Overton LC; Heinrich MC
    Expert Opin Pharmacother; 2014 Mar; 15(4):549-58. PubMed ID: 24405315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
    Komatsu Y; Doi T; Sawaki A; Kanda T; Yamada Y; Kuss I; Demetri GD; Nishida T
    Int J Clin Oncol; 2015 Oct; 20(5):905-12. PubMed ID: 25655899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
    Son MK; Ryu MH; Park JO; Im SA; Kim TY; Lee SJ; Ryoo BY; Park SR; Kang YK
    Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib for cancer.
    Strumberg D; Schultheis B
    Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
    Lyseng-Williamson KA
    BioDrugs; 2013 Oct; 27(5):525-31. PubMed ID: 23975637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
    Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S
    Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
    George S; Wang Q; Heinrich MC; Corless CL; Zhu M; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Tap WD; Yap JT; Van den Abbeele AD; Manola JB; Solomon SM; Fletcher JA; von Mehren M; Demetri GD
    J Clin Oncol; 2012 Jul; 30(19):2401-7. PubMed ID: 22614970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib-induced hyperammonemic encephalopathy.
    Kuo JC; Parakh S; Yip D
    J Clin Pharm Ther; 2014 Aug; 39(4):446-8. PubMed ID: 24707992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
    Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.
    Aprile G; Macerelli M; Giuliani F
    BioDrugs; 2013 Jun; 27(3):213-24. PubMed ID: 23435872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.